The pregnane X receptor (PXR, also known as NR1I2, SXR, or PAR) is a nuclear hormone receptor (NHR) that regulates the transcription of genes involved in xenobiotic metabolism and excretion. PXR agonists include a wide range of structurally diverse endogenous and exogenous compounds such as bile acids, steroid hormones, dietary fat-soluble vitamins, prescription medications, and herbal drugs, as well as environmental chemicals such as pesticides, estrogens, and antiestrogens ([@b28-ehp-118-1412]). PXR agonists can mediate clinically significant drug--drug interactions ([@b9-ehp-118-1412], [@b11-ehp-118-1412]; [@b27-ehp-118-1412]). Furthermore, PXR action in various pathophysiological states indicates that PXR agonists could variably affect human and animal health. For example PXR agonists can impact cholesterol metabolism and the endocrine system ([@b46-ehp-118-1412]; [@b53-ehp-118-1412]) as well as potentiate the toxicity of other environmental contaminants, as reviewed recently ([@b2-ehp-118-1412]). Animal models may not reliably predict human PXR (hPXR)-related problems because of the diversity of PXRs across species ([@b13-ehp-118-1412]; [@b29-ehp-118-1412]), resulting in differences in ligand selectivity ([@b41-ehp-118-1412]). Therefore, the identification and characterization of hPXR agonists is important to human pharmacokinetics and toxicology of environmental chemicals.

Five hPXR crystal structures (1M13, 1NRL, 1SKX, 2O9I, and 2QNV) are available in the Protein Data Bank (PDB) ([@b5-ehp-118-1412]; [@b38-ehp-118-1412]; [@b47-ehp-118-1412], [@b48-ehp-118-1412]; [@b50-ehp-118-1412]), with another structure to be deposited ([@b51-ehp-118-1412]). These structures have enabled characterization of the ligand-binding domain (LBD) and PXR--ligand interactions. The cocrystallized ligands tend to be hydrophobic, with a wide range in shape, size, and chemical composition that can be accommodated in the LBD ([@b12-ehp-118-1412]). The hPXR ligand-binding pocket (LBP) is lined with 28 amino acid residues: 20 hydrophobic, 4 polar, and 4 charged. Because of the large size and flexibility of the LBP, molecules can bind in multiple locations. This creates a challenge for *in silico* methods for predicting hPXR agonists, but many approaches have been evaluated nonetheless ([@b12-ehp-118-1412]). An added complexity to predicting whether a compound binds to PXR is the recent discovery that some molecules can also bind outside the LBD on the PXR surface and act as allosteric antagonists ([@b9-ehp-118-1412], [@b11-ehp-118-1412]). It is also difficult to computationally identify antagonists that would compete with agonist binding in the LBD ([@b50-ehp-118-1412]).

Several previous studies have constructed ligand-based computational models for hPXR agonists employing pharmacophores ([@b1-ehp-118-1412]; [@b10-ehp-118-1412]; [@b9-ehp-118-1412]; [@b36-ehp-118-1412]), quantitative structure--activity relationships (QSARs), and machine learning methods ([@b8-ehp-118-1412], [@b12-ehp-118-1412]; [@b16-ehp-118-1412]; [@b43-ehp-118-1412]; [@b52-ehp-118-1412]). hPXR agonist pharmacophore models have been shown to possess hydrophobic, hydrogen bond acceptor, and hydrogen bond donor features, a finding consistent with the crystallographic structures of hPXR ligand-receptor complexes ([@b1-ehp-118-1412]; [@b9-ehp-118-1412]; [@b10-ehp-118-1412]; [@b36-ehp-118-1412]). These pharmacophore features may also relate closely to a recent analysis in which [@b31-ehp-118-1412] used docking of small probe molecules into the LBD to identify five hot spots. As part of an ongoing analysis of NHRs ([@b13-ehp-118-1412]; [@b35-ehp-118-1412]; [@b34-ehp-118-1412], [@b32-ehp-118-1412], [@b33-ehp-118-1412]), we recently generated a large volume of experimental data for classes of steroidal compounds ([@b13-ehp-118-1412]) and used it to evaluate various modeling approaches such as Bayesian classification modeling with 2-dimensional (2D) fingerprints, various QSAR approaches, and molecular docking into the available hPXR crystal structures ([@b12-ehp-118-1412]). Docking coupled with hybrid scoring 5D-QSAR methods performed significantly better than other QSAR methods in identifying agonists among these steroidal ligands ([@b12-ehp-118-1412]). With a promiscuous protein such as PXR, it is probably important to have global models or methods that can make predictions for a structurally diverse array of molecules rather than for a narrow structural series.

In previous studies we used structure-based docking, employing FlexX (BioSolveIT GmbH, Sankt Augustin, Germany) combined with logistic regression ([@b20-ehp-118-1412]), and GoldScore (Cambridge Crystallographic Data Centre, Cambridge, UK) combined with other descriptors as a weighting factor ([@b23-ehp-118-1412]). Both FlexX and GOLD had mixed success in predicting a large set of structurally diverse hPXR agonists ([@b20-ehp-118-1412]; [@b23-ehp-118-1412]), possibly because of the size and flexibility of the LBP, as described above ([@b12-ehp-118-1412]).

ToxCast represents a major U.S. Environmental Protection Agency (U.S. EPA) initiative for prioritizing the timely toxicity testing of large numbers of pesticides and other industrial chemicals ([@b7-ehp-118-1412]; [@b14-ehp-118-1412]; [@b18-ehp-118-1412], [@b19-ehp-118-1412]; [@b21-ehp-118-1412]) that may indicate various toxicity end points. In this study we initially used docking and scoring approaches to classify the hPXR agonist activity of these ToxCast compounds and prioritized them for *in vitro* screening prior to release of U.S. EPA experimental data. Our aim was to select a small subset of the compounds for testing to show that we could readily identify PXR agonists and PXR nonagonists without the need for screening all the compounds *in vitro*. We have also used the ToxCast data set to further evaluate whether docking coupled with a hybrid scoring scheme was useful as a predictive method for PXR, especially when screening large data sets of molecules. Although most ToxCast compounds are pesticides or other industrial chemicals, in this case there may be some overlap with the chemical space of pharmaceuticals, making this data set of interest for general PXR-agonist prediction. In addition, for comparison and to illustrate the difficulties of using local ligand-based models, we used a recently generated Bayesian model with 115 steroidal PXR agonists and nonagonists ([@b12-ehp-118-1412]) to classify the ToxCast compounds. While the present study was in progress, the ToxCast initiative generated data on all the compounds from the NIH (National Institutes of Health) Chemical Genomics Center (NCGC) ([@b19-ehp-118-1412]). Therefore, we evaluated all available ToxCast hPXR *in vitro* data for these compounds using these computational methods to make predictions.

Materials and Methods
=====================

Materials
---------

We purchased the DPX-2 cell line and the corresponding dosing and culturing medium from Puracyp Inc. (Carlsbad, CA). The creation of a HepG2 (human liver) cell line stably expressing the human Na^+^-taurocholate cotransporter (NTCP) has been previously reported and described in detail ([@b25-ehp-118-1412]). For tissue culture, we obtained BD Falcon Petri dishes from BD Biosciences (San Jose, CA); opaque treated sterile white 96-well assay plates with lids, and flat-bottom treated sterile (white with clear bottom) assay plates from Corning Inc. (Corning, NY). Disposable sterile pipette tips (low-adhesion tips) were purchased from BioTek (Winooski, VT), and the CellTiter-Fluor and Bright Glow assay system from Promega (Madison, WI). We used the Synergy Mx monochromator- based multimode microplate reader, EL406 Combination Washer Dispenser, and Precision XS microplate sample processor (BioTeK) for cell plating, drug dilution and plating, and reagent addition.

Docking and scoring
-------------------

We obtained chemical structures of the ToxCast molecules from the U.S. EPA Distributed Structure-Searchable Toxicity Database Network web site ([@b44-ehp-118-1412]); these structures were docked into the five crystal structures of hPXR (1M13, 1NRL, 1SKX, 2O9I, and 2QNV) using the docking program GOLD (version 4) as described by [@b17-ehp-118-1412]. GOLD uses a genetic algorithm to explore the various conformations of ligands and flexible receptor side chains in the LBP. We performed 20 independent docking runs for each ligand, and the complexes were scored using GoldScore. In all cases before now, the crystal structure ligand was removed, and hydrogen atoms were added to the amino acids. All amino acids within 6 Å of the cocrystallized ligand were identified as the binding site.

From the entire set of ToxCast molecules that were docked to all five crystal structures, we chose 13 high-scoring and 2 low-scoring compounds to form the sample set. In addition, 13 compounds reported by [@b26-ehp-118-1412]---that docked to the five crystal structures and were scored using GoldScore---were added to our sample set. For all 28 compounds in the sample data set, we performed the GoldScore-based classification by choosing 80% of the GoldScore of the corresponding cocrystal ligand as a cutoff for whether a compound was an agonist ([Table 1](#t1-ehp-118-1412){ref-type="table"}). The complexes were also scored using a hybrid scoring scheme, which was designed as GoldScore weighted with similarity scores ([@b23-ehp-118-1412]). The similarity scores were based on 2D similarity ([@b37-ehp-118-1412]; [@b49-ehp-118-1412]) encoded in MDL (Molecular Design Limited) fingerprint keys calculated using Discovery Studio 2.1 (Accelrys, San Diego, CA). The Tanimoto coefficient was used as the metric to compare the resulting molecular fingerprints. The coefficients varied between 0 (dissimilar) and 1 (similar) and were computed for all 28 compounds, with reference to the five cocrystal structure ligands (HYF, SRL, RFP, 444, and CDZ). Further, the weighted docking score of an active compound *i* with *j* conformations can be computed by
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where *s~ij~* is the original GoldScore for the compound *i* in its *j*th conformation and *w~i~* is the similarity score for compound *i* with respect to the cocrystal structure ligand. For each of the 28 compounds, we calculated the average weighted score across all five crystal structures \[see Supplemental Material, Table 1 (doi:10.1289/ehp.1001930)\], and this score (average *S~ij~* \~ 15) was used as a cutoff for the classification. The GoldScores of the compounds and their similarity and weighted scores and classification are listed in Supplemental Material, Table 1. The consensus classification prediction was based on the majority vote across the five structures for each molecule. We classified complexes of all compounds from the ToxCast database with the five crystal structures using the GoldScore and hybrid score as described for the sample data set. We computed an average docking score and an average hybrid score for each crystal structure and used these as cutoff scores for the GoldScore- and hybrid score--based classifications, respectively ([Table 1](#t1-ehp-118-1412){ref-type="table"}).

Predictions based on different docking methods were assessed using a standard set of statistical indicators to evaluate different ligand and docking classification approaches: sensitivity, specificity, overall prediction accuracy, and Matthews correlation coefficient ([@b23-ehp-118-1412]). We generated 2D schematic representations of the ligands in the binding site using the LIGX option in MOE (Chemical Computing Group, Montreal, Quebec, Canada).

Machine learning with 2D descriptors
------------------------------------

We generated a Bayesian classification model using Discovery Studio 2.1 with the Laplacian-corrected Bayesian classifier and molecular descriptors, as previously described for 115 steroidal compounds (namely, androstanes, estratrienes, pregnanes, and bile salts), with hPXR activation determined by a luciferase-based reporter assay ([@b12-ehp-118-1412]). Compounds with Bayesian scores above −5.792 were classed as PXR agonists ([@b12-ehp-118-1412]).

Reporter gene assay with HepG2 cells
------------------------------------

The 13 top-scoring compounds and 2 low-scoring compounds predicted as nonagonists by GoldScore were selected for *in vitro* testing in the HepG2 human liver cell line. We determined hPXR activation in HepG2 cells using a luciferase-based reporter assay, as previously described ([@b13-ehp-118-1412]; [@b24-ehp-118-1412]). Ligands that activated hPXR were classified as strong \[median effective concentration (EC~50~) \< 10 μM\], medium (EC~50~ = 11--50 μM), or weak (EC~50~ \> 50 μM, but still able to activate with at least 10% of the efficacy of 10 μM rifampicin) agonists ([@b13-ehp-118-1412]).

### Reporter gene assay with DPX-2 cells

The tissue culture protocols were performed in a sterile laminar flow hood, and all incubations were carried out at 37°C and 5% CO~2~. When DPX-2 cells were approximately 50--70% confluent, medium was aspirated and cells rinsed with 5 mL phosphate-buffered saline (PBS). The PBS was replaced with 2 mL trypsin/EDTA and incubated for 5 min. Two milliliters medium was added, and the entire mixture was transferred to a centrifuge tube. Cells were centrifuged at 900 rpm for 3 min and resuspended in 5 mL culturing medium; 100 μL cell suspension (corresponding to 25,000 cells) was added to each well of a 96-well plate, using an eight-channel Precision XS microplate sample processor, and incubated overnight. Drug stock solutions (50 mM for each compound) were prepared in DMSO and diluted to 11-point 1:3 compound titrations (50--0 μM) using the Precision XS to serially transfer 75 μL of diluted compounds into 150 μL Puracyp dosing media. The final DMSO concentration was maintained at 0.1% in all dilutions. Medium from DPX-2 cells in 96-well plates was aspirated using an EL406 liquid handler (BioTek); plates were then placed in the Precision XS, and 100 μL dosing medium containing the appropriate concentration of agonist/antagonist was transferred. Each condition was repeated in quadruplicate. After 24 hr, the cell medium was aspirated and cells were redosed as described above. After 48 hr, the cell viability (CellTiter-Fluor) and reporter assay (Bright-Glo) was carried out according to the protocol provided by Promega (Madison, WI).

Log-normalized drug concentrations were fitted to dose--response curves for each compound tested \[relative luminescence units (RLU)\], normalized to control (DMSO-treated) cells (agonist mode) and as a percentage of RLU observed with 10 μM rifampicin (antagonist mode). Curves were fitted using a nonlinear regression model \[variable slope (four parameters) equation\] (GraphPad Prism, version 4.0a; GraphPad Software Inc., La Jolla, CA). In this assay, the standard agonist compound rifampicin had a mean EC~50~ of 1.99 μM.

Results
=======

Sampling ToxCast compounds as potential PXR agonists using docking
------------------------------------------------------------------

In the present study we used molecular docking coupled with hybrid scoring strategies to select compounds for *in vitro* testing based on predicted hPXR activity. Our initial selection of 15 ToxCast compounds was supplemented with 13 compounds from a previous study ([@b26-ehp-118-1412]) that were also included in the ToxCast data set ([Table 2](#t2-ehp-118-1412){ref-type="table"}). Using the docking consensus classification, we correctly classified 15 of 28 (55.6%) molecules from this sample ToxCast data set. Of these 28 compounds, 12 were classified as agonists and 16 as nonagonists, based on the actual ToxCast data. Docking-based classification using GoldScore correctly predicted 8 of 12 agonists and 7 of 16 nonagonists. Using the hybrid scoring scheme, we correctly predicted 7 of 12 agonists and 8 of 16 nonagonists. Mancozeb was classified as a nonagonist in all docking models and was found to be a nonagonist in experimental studies, whereas butafenacil, permethrin, and β-cyfluthrin were all classified as agonists in both the docking and experimental methods based on our HepG2 data and the NCGC ToxCast data ([@b19-ehp-118-1412]) \[[Table 2](#t2-ehp-118-1412){ref-type="table"} and Supplemental Material, Figure 1 (doi:10.1289/ehp.1001930)\]. Foramsulfuron and bensulfuron methyl were both weak agonists in our hPXR luciferase assay in HepG2 cells but were classed as nonagonists based on the U.S. EPA NCGC data generated using the DPX-2 cell line ([@b19-ehp-118-1412]), a derivative of HepG2. These compounds may be hPXR agonists but have only weak activity at high concentrations. With high concentrations of compounds, hPXR activation may not be detected in some cell lines because of cellular toxicity or limited solubility of the compound(s). Similarly, using the hPXR DPX-2 agonist assay, we found generally good agreement with the hPXR HepG2 data, although *Z,E*-fenpyroximate appeared to be a weak hPXR agonist; the cell viability of this compound suggests it is also cytotoxic \[median inhibitory concentration (IC~50~), 0.04; [Table 2](#t2-ehp-118-1412){ref-type="table"}\].

The standard agonist compound rifampicin had a mean EC~50~ of 1.99 μM in DPX-2 cells, which is lower than reported previously ([@b9-ehp-118-1412]) and closer to those reported in other cell assay systems in HepG2 \[EC~50~, 400 nM ([@b15-ehp-118-1412])\] and CV-1 cells \[EC~50~, 700--852 nM ([@b5-ehp-118-1412]); EC~50~, 710 nM ([@b30-ehp-118-1412])\]. The NCGC data ([@b19-ehp-118-1412]) were from DPX-2 cells, which we would expect to yield results similar to our own using DPX-2 cells, but not to our data using HepG2 cells. For example, fenarimol was classified as a nonagonist based on the docking and hybrid scores, whereas it is an agonist according to the NCGC data ([@b19-ehp-118-1412]) and our Bayesian classification. In the present study, the docking scores for this compound were very close to the cutoff scores and hence could not be effectively predicted. This is a limitation of classifying compounds based on docking scores. Hybrid scores, which are designed based on similarity-weighted docking scores, can resolve these limitations only when the test compound has high similarity to the cocrystallized ligand. Compounds such as fenbuconazole and difenzoquat metilsulfate were classified as agonists based on the high GoldScores but were classified as nonagonists in the hybrid scoring scheme because of their low similarity to their respective cocrystalized ligands. NCGC experimental data classified both these compounds as nonagonists ([@b19-ehp-118-1412]).

Comparing NCGC and docking data for all ToxCast compounds
---------------------------------------------------------

Our results with the sample data set suggest that computational docking methods can be used as an effective strategy in prioritizing future ToxCast compounds for *in vitro* testing as PXR agonists before actual testing. To test this hypothesis, we docked all the compounds from the ToxCast database to all five hPXR crystal structures and scored the complexes using GoldScore and hybrid scoring functions. Based on the *in vitro* NCGC ToxCast data ([@b19-ehp-118-1412]), 65 compounds have been classified as agonists of hPXR and 246 as nonagonists ([@b45-ehp-118-1412]). In the present study, GoldScore-based classification correctly predicted 48 agonists and 120 nonagonists, whereas the hybrid scoring scheme correctly predicted 45 agonists and 137 nonagonists \[Supplemental Material, Table 2 (doi:10.1289/ehp.1001930)\]. The rest of the compounds were either false positives or false negatives. The sensitivity of scoring schemes for correctly predicting hPXR agonists with the NCGC data ([@b19-ehp-118-1412]) was 73.8% and 69.2% for GoldScore and hybrid score classification schemes, respectively.

Predictions using the steroidal Bayesian hPXR model
---------------------------------------------------

The hPXR agonist predictions using the Bayesian model based on steroidal compounds ([@b12-ehp-118-1412]) classified all compounds other than mancozeb as agonists, based on the specified activity cutoff ([Table 2](#t2-ehp-118-1412){ref-type="table"}).

Testing for hPXR antagonists and allosteric antagonists
-------------------------------------------------------

We evaluated whether some of the molecules selected from ToxCast by docking (mesosulfuron-methyl, bensulfuron methyl, esfenvalerate, *Z,E*-fenpyroximate, α-cypermethrin, β-cyfluthrin, and permethrin) were also potential PXR antagonists or allosteric antagonists ([@b9-ehp-118-1412], [@b11-ehp-118-1412]) in the presence of rifampicin. Our results for these compounds tested with the DPX-2 cell assay suggest that they were not antagonists or allosteric antagonists (data not shown).

Discussion
==========

Recent studies have showed the complexity and challenges of producing predictive computational models for hPXR ([@b12-ehp-118-1412]). In the present study we used docking to analyze the ToxCast compounds and select molecules to validate the approach of identifying compounds of interest from large data sets without experimentally screening the whole data set. Subsequently, the release of the NCGC data in which the whole data set was experimentally screened provided additional data to compare with our own laboratory hPXR activation data and our computational predictions in five crystal structures. An advantage of using these different cell systems is that some are more sensitive than others and thus may identify additional compounds as agonists compared with using a single cell type ([Table 2](#t2-ehp-118-1412){ref-type="table"}). For example, diethylhexyl phthalate, esfenvalerate, α-cypermethrin, β-cyfluthrin, and permethrin were more active in HepG2 cells compared with NCGC DPX-2 cells ([Table 2](#t2-ehp-118-1412){ref-type="table"}). Fenarinol, imazalil, alachlor, and fipronil were classed as active in NCGC DPX-2 cells but not in HeLa cells \[as reported previously by [@b26-ehp-118-1412]\], whereas fenbuconazole, and prochloraz were more active in HeLa cells than DPX-2 cells ([Table 2](#t2-ehp-118-1412){ref-type="table"}) ([@b26-ehp-118-1412]).

Possible reasons for these differences include non--liver-type cells possibly lacking transporters (or expressing different ones) that can influence drug entry/efflux or may show differential toxicity. This is a problem with conjugated steroids and bile salts. We are not sure if this is the case for the pesticides and industrial chemicals studied here. HeLa cells \[used by [@b26-ehp-118-1412]\], HepG2 cells, and hepatocytes are markedly different in terms of their cells of origin (HeLa and HepG2 are essentially cancer cell lines). The HeLa cell line may have different levels of corepressors and coactivators that affect the function of PXR differently than in liver cell lines. The transactivation of reporters varies in both cell lines to a degree. For example, HNF4α-mediated effects on PXR are greater in HeLa cells than in HepG2 cells, suggesting weaker PXR transactivation profiles in HeLa versus hepatic-derived cell lines ([@b42-ehp-118-1412]). One could perhaps use primary human hepatocytes for such studies, but they have the limitations of cost, limited supply, and variability. It is also possible that cell lines differentially metabolize the test compounds, which could also affect PXR activation results. In the pressent study (and for the NCGC data), the metabolism of the compound in the *in vitro* assay was not analyzed. Because radioligand binding is not a viable option for high-throughput screening for PXR and additionally would probably not give information on actual overall activity, there may be differences between docking and functional assays, a situation likely not unique to PXR.

All compounds from the ToxCast data set were docked to the five hPXR crystal structures and scored using GoldScore and hybrid scoring schemes. When molecular docking is used as a tool for classification studies, the question arises as to what docking scores should be considered as a cutoff. Because there are no standard rules governing the choice of cutoff scores, in the past we have designed hybrid scoring schemes that used similarity scores derived from molecular shapes as a weighting factor ([@b23-ehp-118-1412]). The goal of the hybrid scoring schemes is to increase the gap between hPXR agonists and hPXR nonagonists and thus ease classification of compounds. In this study we derived cutoff scores either by using the docking scores of the cocrystal structure ligands or by averaging the docking or weighted scores of all the ligands binding to the five crystal structures ([Table 1](#t1-ehp-118-1412){ref-type="table"}). Predictions from the complete ToxCast data set performed marginally better than the sample data set, thereby emphasizing the utility of the approach to classify large data sets prior to *in vitro* testing. The hybrid scoring scheme had a sensitivity of approximately 69%, specificity of approximately 56%, overall prediction accuracy of approximately 59%, and a Matthews correlation coefficient of 0.2 for classifying all ToxCast compounds based on the NCGC data ([@b19-ehp-118-1412]), whereas the GoldScore-based scheme provided the best sensitivity of approximately 74% ([Table 3](#t3-ehp-118-1412){ref-type="table"}). Classification studies also benefit from the availability of multiple crystal structures of the protein in complex with a variety of ligands. Although all the cocrystallized ligands bind to the same binding site and the crystal structures superimpose within approximately 1 Å root mean squared deviation, the size, nature, and chemical composition of these ligands are very different ([@b12-ehp-118-1412]). In addition, the availability of multiple crystal structures of promiscuous proteins such as PXR helps improve sampling of the docking mode of these compounds. This is evident in the range of docking scores we obtained for each compound across each of the five crystal structures \[see Supplemental Material, Table 2 (doi:10.1289/ehp.1001930)\], which also emphasizes that averaging methods to get a single score should not be used in these cases. Instead, we classified each docked complex using the cutoff scores listed in [Table 1](#t1-ehp-118-1412){ref-type="table"} and then used a majority vote (3 of 5) method for consensus classification for both GoldScore and hybrid scoring schemes.

The ToxCast data set also consists of compounds that have diverse structure, size, and chemical composition, albeit with similar functionality important for interactions with PXR \[see Supplemental Material, Figure 1 (doi:10.1289/ehp.1001930)\]. Thus, classifying this diverse data set by similarity-weighted scoring schemes with approximately 69% sensitivity for predicting agonists is encouraging (considering the promiscuity of the receptor), and the statistics are comparable with or better than our previous data from studies using the GoldScore and hybrid scoring schemes ([@b12-ehp-118-1412]; [@b23-ehp-118-1412]). These data should improve in the future as docking tools develop; however, the current approaches may be more accurate with other less-promiscuous nuclear receptors such as the estrogen and androgen receptors. The hybrid scoring scheme performed better for the ToxCast data (sensitivity and Matthews correlation coefficient were consistently higher; [Table 3](#t3-ehp-118-1412){ref-type="table"}) compared with a series of 119 steroidal molecules we previously used with average sensitivity of 52%, specificity of 50.34%, accuracy of 50.76%, and Matthews correlation coefficient of 0.02% ([@b23-ehp-118-1412]). This suggests that there may be differences in docking utility depending on compound class and therefore value in evaluating molecules beyond drugs to gain a broader insight into potential PXR agonists among industrial chemicals, pollutants, natural products, and so on.

We also compared docking with a ligand-based QSAR method based on steroidal compounds to provide a further benchmark, and in this case its performance was poor, possibly for several reasons. First, many groups have illustrated the importance of chemical space coverage and the applicability domain of ligand-based models ([@b4-ehp-118-1412], [@b3-ehp-118-1412]; [@b6-ehp-118-1412]; [@b8-ehp-118-1412]; [@b22-ehp-118-1412], [@b23-ehp-118-1412]; [@b37-ehp-118-1412]; [@b39-ehp-118-1412], [@b40-ehp-118-1412]). When we analyzed the molecular space covered by the steroids in the ligand-based Bayesian model compared with the ToxCast compounds, we found that they can be clearly separated \[see Supplemental Material, Figure 2 (doi:10.1289/ehp.1001930)\], which is indicative of little overlap. This would suggest it may be difficult for this local hPXR model to reliably predict compounds that are not steroidal. Thus, it may be important in future work to develop a separate Bayesian model with the ToxCast compounds to predict hPXR agonists added to later versions of the database. Our ligand-based data also confirm that to predict diverse compounds with likely hPXR agonist activity, methods that are more generic or global in nature are required that can capture some of the flexibility of the ligand-binding domain ([@b12-ehp-118-1412]). Although ToxCast is a major U.S. EPA initiative for prioritizing toxicity testing of large numbers of pesticides and other chemicals ([@b7-ehp-118-1412]; [@b14-ehp-118-1412]; [@b18-ehp-118-1412], [@b19-ehp-118-1412]; [@b21-ehp-118-1412]), we suggest that it also represents a unique opportunity to evaluate various predictive computational approaches used for toxicology end points prospectively in addition to the many ways to mine the data retrospectively. In the present study we have addressed only a tiny fraction of the data produced to date and perhaps raised the question that focusing on one cell line for a single nuclear receptor, such as hPXR, may be too simplistic.

We still can learn a great deal from the efficient combination of *in vitro* and *in silico* approaches, such that multiple iterations of prediction may yield a more cost-effective route to selecting compounds for testing from a large database. The ToxCast data set therefore represents an important and evolving basis for evaluating computational methods used in toxicological assessments of compounds important for environmental and health applications. Although we did not identify any PXR antagonists or allosteric antagonists, based on the few samples tested, the complete ToxCast data set could be more exhaustively studied with both computational and *in vitro* methods in the future ([@b11-ehp-118-1412]). Current opinion suggests that classical competitive antagonists for PXR that bind in the ligand-binding pocket may be difficult to identify ([@b50-ehp-118-1412]) compared with allosteric antagonists that bind elsewhere on the protein surface ([@b9-ehp-118-1412], [@b11-ehp-118-1412]). It is therefore important to evaluate whether a compound may be a more selective allosteric antagonist, because this could outweigh any potential PXR agonist activity *in vivo*.

Supplemental Material is available online (doi:10.1289/ehp.1001930 via <http://dx.doi.org/>).
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###### 

GoldScores for the PXR cocrystallized ligands and their corresponding cutoff scores used for classification of a sample data set and all ToxCast compounds using GoldScore and 2D similarity-weighted hybrid score.

  PXR structure (PDB code)   Cocrystallized ligand   Cutoff score for sample data set   Cutoff score for ToxCast data set             
  -------------------------- ----------------------- ---------------------------------- ----------------------------------- ---- ---- ----
  1M13                       HYF                     82.06                              66                                  15   51   13
  1NRL                       SRL                     48.31                              39                                  15   46   14
  1SKX                       RFP                     65.44                              52                                  15   48   15
  2O9I                       444                     48.69                              39                                  15   46   13
  2QNV                       CDZ                     55.19                              44                                  15   44   11

###### 

Summary of predicted and experimental data for sample ToxCast data set compounds.

  Compound                                                    Docking classification[a](#tfn2-ehp-118-1412){ref-type="table-fn"}   Bayesian score (classification)   U.S. EPA ToxCast (NCGC) hPXR DPX-2 classification \[EC~50~ (μM)\][b](#tfn3-ehp-118-1412){ref-type="table-fn"}   HepG2 hPXR EC~50~ (μM)[c](#tfn4-ehp-118-1412){ref-type="table-fn"}   Efficacy relative to 10 μM rifampicin[c](#tfn4-ehp-118-1412){ref-type="table-fn"}   Cell viability IC~50~ (μM)[c](#tfn4-ehp-118-1412){ref-type="table-fn"}   DPX-2 hPXR EC~50~ (μM)[c](#tfn4-ehp-118-1412){ref-type="table-fn"}
  ----------------------------------------------------------- -------------------------------------------------------------------- --------------------------------- --------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------- ----------------------------------------------------------------------------------- ------------------------------------------------------------------------ --------------------------------------------------------------------
  Mancozeb                                                    N                                                                    −7.253 (N)                        N                                                                                                               X                                                                                                                                                                                                                                 
  Mesosulfuron-methyl                                         A                                                                    −1.589 (A)                        N                                                                                                               X                                                                                                                                                        X                                                                        X
  Diethylhexyl phthalate                                      A                                                                    1.943 (A)                         A (20.75)                                                                                                       1.8 (S)                                                              0.63                                                                                                                                                         
  Methyl hydrogen phthalate                                   N                                                                    1.868 (A)                         N                                                                                                                                                                                                                                                                                                                                                 
  Bensulide                                                   A                                                                    −1.165 (A)                        A (1.57)                                                                                                                                                                                                                                                                                                                                          
  Foramsulfuron                                               A                                                                    −1.653 (A)                        N                                                                                                               \> 50 (W)                                                                                                                                                                                                                         
  Bensulfuron methyl                                          A                                                                    0.601 (A)                         N                                                                                                               89.4 (W)                                                             0.18                                                                                X                                                                        X
  Esfenvalerate                                               A                                                                    5.796 (A)                         A (26.98)                                                                                                       1.5 (S)                                                              0.64                                                                                X                                                                        8.94 (S)
  *Z,E*-fenpyroximate                                         A                                                                    2.613 (A)                         N                                                                                                               X                                                                                                                                                        0.04                                                                     32.74 (M)
  Butafenacil                                                 A                                                                    3.317 (A)                         N                                                                                                               6 (S)                                                                0.53                                                                                                                                                         
  α-Cypermethrin                                              A                                                                    5.346 (A)                         A (18.3)                                                                                                        1.6 (S)                                                              0.54                                                                                X                                                                        0.88 (S)
  Triflusulfuron methyl                                       A                                                                    −1.998 (A)                        N                                                                                                               --                                                                                                                                                                                                                                
  β-Cyfluthrin                                                A                                                                    5.346 (A)                         A (19.7)                                                                                                        2.5 (S)                                                              0.54                                                                                \> 100                                                                   18.2 (M)
  Permethrin                                                  A                                                                    4.83 (A)                          A (20.26)                                                                                                       5.4 (S)                                                              0.53                                                                                X                                                                        29.09 (M)
  Oxasulfuron                                                 A                                                                    −1.942 (A)                        N                                                                                                                                                                                                                                                                                                                                                 
  Fenarimol[d](#tfn5-ehp-118-1412){ref-type="table-fn"}       N                                                                    4.791 (A)                         A (20.29)                                                                                                                                                                                                                                                                                                                                         
  Propiconazole[d](#tfn5-ehp-118-1412){ref-type="table-fn"}   A                                                                    3.475 (A)                         A (36.81)                                                                                                                                                                                                                                                                                                                                         
  Fenbuconazole[d](#tfn5-ehp-118-1412){ref-type="table-fn"}   A                                                                    5.390 (A)                         N                                                                                                                                                                                                                                                                                                                                                 
  Prochloraz[d](#tfn5-ehp-118-1412){ref-type="table-fn"}      A                                                                    2.705 (A)                         N                                                                                                                                                                                                                                                                                                                                                 
  Imazalil[d](#tfn5-ehp-118-1412){ref-type="table-fn"}        N                                                                    3.466 (A)                         A (36.54)                                                                                                                                                                                                                                                                                                                                         
  Oxadiazon[d](#tfn5-ehp-118-1412){ref-type="table-fn"}       A                                                                    4.663 (A)                         A (5.49)                                                                                                                                                                                                                                                                                                                                          
  Alachlor[d](#tfn5-ehp-118-1412){ref-type="table-fn"}        N                                                                    7.842 (A)                         A (15.35)                                                                                                                                                                                                                                                                                                                                         
  2,4-D[d](#tfn5-ehp-118-1412){ref-type="table-fn"}           N                                                                    −0.563 (A)                        N                                                                                                                                                                                                                                                                                                                                                 
  Diuron[d](#tfn5-ehp-118-1412){ref-type="table-fn"}          N                                                                    4.357 (A)                         N                                                                                                                                                                                                                                                                                                                                                 
  Atrazine[d](#tfn5-ehp-118-1412){ref-type="table-fn"}        N                                                                    −2.825 (A)                        N                                                                                                                                                                                                                                                                                                                                                 
  Fipronil[d](#tfn5-ehp-118-1412){ref-type="table-fn"}        N                                                                    −0.033 (A)                        A (12.55)                                                                                                                                                                                                                                                                                                                                         
  Thiabendazole[d](#tfn5-ehp-118-1412){ref-type="table-fn"}   N                                                                    2.879 (A)                         N                                                                                                                                                                                                                                                                                                                                                 
  Carbaryl[d](#tfn5-ehp-118-1412){ref-type="table-fn"}        N                                                                    1.265 (A)                         N                                                                                                                                                                                                                                                                                                                                                 

Abbreviations: 2,4-D, 2,4-dichlorophenoxyacetic acid; A, agonist; M, medium agonist; N, nonagonist; S, strong agonist; W, weak agonist; X, no activity measurable. Values with Bayesian scores greater than −5.792 were classed as PXR agonists based on the model output ([@b12-ehp-118-1412]). Docking classification was performed using GoldScore, with cutoff values listed in [Table 1](#t1-ehp-118-1412){ref-type="table"}. Agonists were classified based on the following criteria used in a previous study ([@b13-ehp-118-1412]): S, EC~50~ \< 10 μM; M, EC~50~ 11--50 μM; W, EC~50~ \> 50 μM (but with activation at least 10% that of 10 μM rifampicin).

Based on data provided in Supplemental Material, Table 1 (doi:10.1289/ehp.1001930).

For NCGC data ([@b19-ehp-118-1412]), the cutoff for activity was 200 μM.

Assays performed in the present study.

Componds with previously published data generated in HeLa cells ([@b26-ehp-118-1412]).

###### 

Statistical parameters for the hPXR consensus docking results from the sample data set (*n* = 28) and complete (all; *n* = 308) ToxCast data set.

  Data set              SE      SP      Q       C
  --------------------- ------- ------- ------- ------
  Sample data set, gs   66.67   46.67   55.55   0.13
  Sample data set, hs   58.33   50.00   53.57   0.08
  All ToxCast, gs       73.85   51.22   55.95   0.20
  All ToxCast, hs       69.23   55.69   58.52   0.20

Abbreviations: C, Matthews correlation coefficient; gs, GoldScore; hs, hybrid scoring schemes; Q, overall prediction accuracy; SE, sensitivity; SP, specificity.
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